Skip to main content
SAM CHUN DANG PHARM CO. LTD logo

SAM CHUN DANG PHARM CO. LTD — Investor Relations & Filings

Ticker · 000250 ISIN · KR7000250001 KO Manufacturing
Open in API
Filings indexed 224 across all filing types
Latest filing 2024-03-22 M&A Activity
Country KR South Korea
Listing KO 000250

About SAM CHUN DANG PHARM CO. LTD

http://www.scd.co.kr/english/scd/index.…

SAM CHUN DANG PHARM CO. LTD. is a pharmaceutical company focused on the development, manufacturing, and sale of medications. The company specializes in ophthalmic products, establishing itself as a significant player in the generic eye care market. Its portfolio also extends to other therapeutic areas, including antibiotics and medications for the circulatory system. The company produces a range of ethical (prescription) and over-the-counter (OTC) drugs in both sterile and non-sterile forms. Manufacturing operations adhere to international quality standards, holding both US and EU Good Manufacturing Practice (GMP) certifications.

Recent filings

Filing Released Lang Actions
투자판단관련주요경영사항
M&A Activity Classification · 100% confidence The document is a regulatory filing from Samchundang Pharm regarding a major business decision, specifically the signing of an exclusive supply and sales agreement for a biosimilar drug in Europe. This type of disclosure, which details a significant contract or business development, is classified as a general regulatory filing (RNS) as it does not fit into specific categories like M&A (which usually involves corporate takeovers) or other specialized financial reports.
2024-03-22 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a formal regulatory filing titled '감사보고서 제출' (Submission of Audit Report) submitted by Samchundang Pharm. It contains detailed financial tables including consolidated and separate financial statements, audit opinions, and financial ratios. While it provides audit-related data, it is a standard regulatory disclosure of the audit report results rather than the full, multi-page audit report document itself. According to the 'Menu vs Meal' rule, this is a regulatory filing announcing the submission of the audit report to the exchange. FY 2023
2024-03-20 Korean
사업보고서 (2023.12)
Annual Report Classification · 100% confidence The document is explicitly titled '사업보고서' (Business Report/Annual Report) for the 80th fiscal year (2023.01.01 - 2023.12.31). It contains comprehensive company information, financial data, management discussion, and governance details, which are characteristic of a full Annual Report (10-K equivalent in the Korean market). FY 2023
2024-03-20 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Notice of Annual General Meeting' (주주총회소집공고) for Samchundang Pharm Co., Ltd. It contains the meeting agenda, details on director appointments, financial statements, and voting procedures. This type of document is standard for providing shareholders with the necessary information to vote at an upcoming AGM, which falls under the 'Proxy Solicitation & Information Statement' category.
2024-03-08 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for Samchundang Pharm. It outlines the date, location, and agenda items (financial statements, director appointments, remuneration limits) for the upcoming Annual General Meeting. This document serves as the official proxy solicitation and information statement provided to shareholders to inform them of the meeting and request their participation/votes. Therefore, it falls under the Proxy Solicitation & Information Statement category.
2024-02-27 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from a Korean company (Samchundang Pharm) regarding a significant change in financial structure (revenue/profit fluctuation of 30% or more). This is a standard regulatory disclosure requirement in the Korean market (DART system) for listed companies to report preliminary financial results before the final audit is completed. Since it provides specific financial figures and reasons for the change, it functions as an Earnings Release (ER) for the fiscal period. FY 2023
2024-02-02 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.